Adity Chopra

Adity Chopra

Auto-generated profile, based on publicly available information

Adity Chopra

Department of Immunology, Oslo University Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ASArne Søraas
Arne Søraas
GGGunnveig Grødeland
Gunnveig Grødeland
BGBeathe Kiland Granerud
Beathe Kiland Granerud
TUThor Ueland
Thor Ueland
ALAndreas Lind
Andreas Lind
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals.Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively.Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters.Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant.Funding: The study was funded by the Oslo University Hospital, and by grants from The Coalition for Epidemic Preparedness Innovations, Research Council of Norway (no 312780, 324272), South-Eastern Norway Regional Health Authority (no 2019067, 2021071, 10357, 2021047, 33612, 2021087, 2017092), EU Horizon 2020 grant no 848099, a philantropic donation from Vivaldi Invest A/S, and The European Virus Archive Global.

28 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TTTrung The Tran
Trung The Tran
EVEline Benno Vaage
Eline Benno Vaage
AMAdi Mehta
Adi Mehta
ACAdity Chopra
Adity Chopra
AKAnette Kolderup
Anette Kolderup
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 sera. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.

14 February 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Open access
KJKristin Kaasen Jørgensen
Kristin Kaasen Jørgensen
MHMarte Lie Høivik
Marte Lie Høivik
ACAdity Chopra
Adity Chopra
JBJūratė Šaltytė Benth
Jūratė Šaltytė Benth
PRPetr Ricanek
Petr Ricanek
JJJørgen Jahnsen
Jørgen Jahnsen
Immune responses following SARS-CoV-2 vaccination in patients with inflammatory bowel disease (IBD) are not well characterized. The aims of this study were to explore the serological response assoc...

27 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ASArne Søraas
Arne Søraas
GGGunnveig Grødeland
Gunnveig Grødeland
BGBeathe Kiland Granerud
Beathe Kiland Granerud
TUThor Ueland
Thor Ueland
ALAndreas Lind
Andreas Lind
FLFridtjof Lund-Johansen
Fridtjof Lund-Johansen
Background The Omicron variant of SARS-CoV-2 is now overtaking the Delta variant in many countries. Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron may indicate that the higher rate of transmission is due to evasion from vaccine-induced immunity. However, there is little information about activation of recall responses to Omicron in vaccinated individuals. Methods We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the SARS-CoV-2 spike and nucleocapsid proteins and spike peptide-induced interferon gamma in whole blood. Both the Omicron and the Delta infected patients had a mild and transient increase in inflammatory parameters. Interpretation The results suggest that vaccine-induced immunological memory yields similar coverage for the Omicron and Delta variants.